{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:35:38Z","timestamp":1766054138852,"version":"3.48.0"},"reference-count":55,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FEDER\u2014Fundo Europeu de Desenvolimento Regional"},{"name":"Portuguese funds"},{"name":"FMUP","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"FMUP","award":["PRR-09\/C06-834I07\/2024.P11721"],"award-info":[{"award-number":["PRR-09\/C06-834I07\/2024.P11721"]}]},{"name":"FMUP","award":["2024.18026.PEX"],"award-info":[{"award-number":["2024.18026.PEX"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJTM"],"abstract":"<jats:p>Background\/Objectives: Understanding the pharmacokinetics (PK) of antiepileptic and anti-inflammatory drugs under different physiological conditions is essential for optimizing therapy. Phenytoin, a widely used antiepileptic, and indomethacin, a nonsteroidal anti-inflammatory drug, are frequently prescribed in women of reproductive age. This study aimed to evaluate the influence of age, pregnancy, and dosing regimens on the PK of both drugs, as well as to investigate potential drug\u2013drug interactions (DDIs). Methods: PK parameters of phenytoin and indomethacin were systematically analyzed in women aged 20\u201345 years under non-pregnant and pregnant conditions. Different dosing regimens were compared, and coadministration studies were conducted to assess DDI. Results: Phenytoin demonstrated stable absorption and bioavailability across ages and during pregnancy. Single daily dosing (300 mg once daily) yielded slightly higher peak concentration (Cmax) values, while fractionated dosing (100 mg q8h) produced significantly higher drug exposure (AUC) and absorption fraction, particularly with prolonged administration, reflecting saturable metabolism. During pregnancy, systemic exposure (Cmax and AUC) was modestly reduced, while absorption and distribution remained unchanged. Indomethacin showed minimal age-related variability and linear pharmacokinetics across dosing regimens. In pregnancy, exposure was reduced (lower Cmax and AUC) with delayed Tmax, indicating slower absorption. Importantly, no PK DDI was observed, as indomethacin parameters remained unchanged except for Tmax, which was lower in the interaction scenario compared with baseline, suggesting a faster absorption rate without affecting overall exposure or peak concentration in the presence of phenytoin. Conclusions: Phenytoin and indomethacin exhibit stable and predictable PK across ages and during pregnancy, with dose-dependent characteristics that align with their known metabolic profiles. The absence of clinically relevant DDI supports their safe concomitant use. These findings provide preliminary reassuring evidence for clinicians and contribute to a better understanding of their pharmacological behavior in diverse patient populations.<\/jats:p>","DOI":"10.3390\/ijtm5040058","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:06:56Z","timestamp":1766052416000},"page":"58","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive PBPK Evaluation of Phenytoin and Indomethacin: Dose, Age, Pregnancy and Drug\u2013Drug Interaction Insights"],"prefix":"10.3390","volume":"5","author":[{"given":"Mariana","family":"Godinho","sequence":"first","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-4957","authenticated-orcid":false,"given":"Lara","family":"Marques","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Smolina, K., Hanley, G.E., Mintzes, B., Oberlander, T.F., and Morgan, S. (2015). Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002\u20132011: A Population-Based Cohort Study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128312"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/pds.4577","article-title":"Trends in Prescription Drug Use during Pregnancy and Postpartum in Norway, 2005 to 2015","volume":"27","author":"Engeland","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejogrb.2016.04.015","article-title":"European Board and College of Obstetrics and Gynaecology (EBCOG)","volume":"201","author":"Templeton","year":"2016","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_4","unstructured":"User, G. (2025, October 14). EMA Releases Guidelines on Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials. Available online: https:\/\/www.clinicalpathwaysresearch.com\/blog\/2025\/8\/11\/ema-releases-guidelines-on-inclusion-of-pregnant-and-breastfeeding-individuals-in-clinical-trials."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.whi.2012.10.003","article-title":"Enrolling Pregnant Women: Issues in Clinical Research","volume":"23","author":"Blehar","year":"2013","journal-title":"Womens Health Issues Off. Publ. Jacobs Inst. Womens Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3138\/ijfab.1.2.5","article-title":"The Second Wave: Toward Responsible Inclusion of Pregnant Women in Research","volume":"1","author":"Lyerly","year":"2008","journal-title":"Int. J. Fem. Approaches Bioeth."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13063-017-2402-9","article-title":"Fair Inclusion of Pregnant Women in Clinical Trials: An Integrated Scientific and Ethical Approach","volume":"19","author":"Oudijk","year":"2018","journal-title":"Trials"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/cpt.1748","article-title":"Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling","volume":"107","author":"Freriksen","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"151221","DOI":"10.1016\/j.semperi.2020.151221","article-title":"Drugs in Pregnancy: Pharmacologic and Physiologic Changes That Affect Clinical Care","volume":"44","author":"Pinheiro","year":"2020","journal-title":"Semin. Perinatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/cpt.1435","article-title":"Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation","volume":"105","author":"Tornio","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","article-title":"National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units Temporal Changes in Drug Metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during Pregnancy","volume":"192","author":"Tracy","year":"2005","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0009-9236(97)90118-1","article-title":"Induction of CYP2D6 in Pregnancy","volume":"62","author":"Wadelius","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3109\/00498254.2011.627477","article-title":"Application of PBPK Modelling in Drug Discovery and Development at Pfizer","volume":"42","author":"Jones","year":"2012","journal-title":"Xenobiotica Fate Foreign Compd. Biol. Syst."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/psp4.33","article-title":"Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK","volume":"4","author":"Wagner","year":"2015","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_15","first-page":"787","article-title":"Inhibition of Human Premature Labor by Indomethacin","volume":"44","author":"Zuckerman","year":"1974","journal-title":"Obstet. Gynecol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/0002-9378(80)90629-8","article-title":"The Inhibition of Premature Labor with Indomethacin","volume":"136","author":"Niebyl","year":"1980","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/cpt1978236658","article-title":"Relation between Plasma Concentration of Indomethacin and Its Effect on Prostaglandin Synthesis and Platelet Aggregation in Man","volume":"23","author":"Rane","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_18","unstructured":"Royal College of Obstetricians & Gynaecologists (2016). Epilepsy in Pregnancy, RCOG. Available online: https:\/\/www.rcog.org.uk\/media\/rzldnacf\/gtg68_epilepsy.pdf."},{"key":"ref_19","first-page":"1489","article-title":"Epilepsy in Women","volume":"66","author":"Morrell","year":"2002","journal-title":"Am. Fam. Physician"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.51.4.949","article-title":"Management Issues for Women with Epilepsy: A Review of the Literature","volume":"51","author":"Zahn","year":"1998","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0b013e3181a6b2f8","article-title":"Practice Parameter Update: Management Issues for Women with Epilepsy\u2013Focus on Pregnancy (an Evidence-Based Review): Obstetrical Complications and Change in Seizure Frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society","volume":"73","author":"Harden","year":"2009","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal Antiepileptic Drug Exposure and Cognitive Outcomes at Age 6 Years (NEAD Study): A Prospective Observational Study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"106838","DOI":"10.1016\/j.ejps.2024.106838","article-title":"Application of Physiologically Based Pharmacokinetic Modeling of Novel Drugs Approved by the U.S. Food and Drug Administration","volume":"200","author":"Sun","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e0139762","DOI":"10.1371\/journal.pone.0139762","article-title":"Development of Physiologically Based Pharmacokinetic\/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy","volume":"10","author":"Alqahtani","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rodriguez-Vera, L., Yin, X., Almoslem, M., Romahn, K., Cicali, B., Lukacova, V., Cristofoletti, R., and Schmidt, S. (2023). Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug-Drug Interactions of Phenytoin. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15102486"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e108190","DOI":"10.1371\/journal.pone.0108190","article-title":"Clinical Validation and Implications of Dried Blood Spot Sampling of Carbamazepine, Valproic Acid and Phenytoin in Patients with Epilepsy","volume":"9","author":"Kong","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2125.1982.tb01981.x","article-title":"Plasma Protein Binding of Phenytoin in 100 Epileptic Patients","volume":"14","author":"Peterson","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0022-3565(25)29239-4","article-title":"The Metabolism of Indomethacin in Man","volume":"181","author":"Duggan","year":"1972","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.115.066845","article-title":"Prediction of Drug-Drug Interactions Arising from CYP3A Induction Using a Physiologically Based Dynamic Model","volume":"44","author":"Almond","year":"2016","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_30","unstructured":"(2025, November 06). Indomethacin: MedlinePlus Drug Information, Available online: https:\/\/medlineplus.gov\/druginfo\/meds\/a681027.html."},{"key":"ref_31","unstructured":"Buckinghamshire Healthcare NHS Trust (2022). Guideline 73FM.6: Phenytoin Information for Prescribing, Monitoring and Administration in Adults, NHS. Available online: https:\/\/www.bucksformulary.nhs.uk\/docs\/Guideline_73FM.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00008571-200110000-00005","article-title":"Phenytoin Metabolic Ratio: A Putative Marker of CYP2C9 Activity in Vivo","volume":"11","author":"Caraco","year":"2001","journal-title":"Pharmacogenetics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40262-014-0133-6","article-title":"Pharmacokinetics of Indomethacin in Pregnancy","volume":"53","author":"Rytting","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1365-2125.2012.04446.x","article-title":"Predicted Metabolic Drug Clearance with Increasing Adult Age","volume":"75","author":"Polasek","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-Related Changes in Pharmacokinetics and Pharmacodynamics: Basic Principles and Practical Applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/00002512-200118110-00005","article-title":"Liver Function and Phase I Drug Metabolism in the Elderly: A Paradox","volume":"18","author":"Schmucker","year":"2001","journal-title":"Drugs Aging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2165\/00003088-199732040-00002","article-title":"Clinical Pharmacokinetics of Naproxen","volume":"32","author":"Davies","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/psp4.12274","article-title":"Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations","volume":"7","author":"Ke","year":"2018","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_39","unstructured":"Rowland, M., and Tozer, T.N. (2011). Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, Wolters Kluwer Health\/Lippincott William & Wilkins."},{"key":"ref_40","unstructured":"(2025, October 14). Applied Clinical Pharmacokinetics, 3e|AccessPharmacy|McGraw Hill Medical. Available online: https:\/\/accesspharmacy.mhmedical.com\/book.aspx?bookID=1374."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5935\/MedicalExpress.2014.02.02","article-title":"Clinical Pharmacology of Ibuprofen in Preterm Infants: A Meta-Analysis of Published Data","volume":"1","author":"Pacifici","year":"2014","journal-title":"Med. Express"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003088-197904030-00001","article-title":"Clinical Pharmacokinetics of Phenytoin","volume":"4","author":"Richens","year":"1979","journal-title":"Clin. Pharmacokinet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically Relevant Drug Interactions with Antiepileptic Drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic Drugs--Best Practice Guidelines for Therapeutic Drug Monitoring: A Position Paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Coppola, P., Kerwash, E., Nooney, J., Omran, A., and Cole, S. (2022). Pharmacokinetic Data in Pregnancy: A Review of Available Literature Data and Important Considerations in Collecting Clinical Data. Front. Med., 9.","DOI":"10.3389\/fmed.2022.940644"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.2008.1","article-title":"Effects of Pregnancy on CYP3A and P-Glycoprotein Activities as Measured by Disposition of Midazolam and Digoxin: A University of Washington Specialized Center of Research Study","volume":"84","author":"Hebert","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/j.semperi.2015.08.003","article-title":"Pharmacokinetics of Drugs in Pregnancy","volume":"39","author":"Feghali","year":"2015","journal-title":"Semin. Perinatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/jcph.2412","article-title":"Indomethacin Pharmacokinetics and Pharmacodynamics in Pregnancies with Preterm Labor: The Need for Dose-Ranging Trials","volume":"64","author":"Balevic","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"ref_49","unstructured":"Brunton, L.L., Hilal-Dandan, R., and Knollmann, B.C. (2017). Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination. Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics, McGraw-Hill Education."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00007691-199001000-00008","article-title":"Protein Binding of Antiepileptic Drugs during Pregnancy, Labor, and Puerperium","volume":"12","author":"Bardy","year":"1990","journal-title":"Ther. Drug Monit."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2215\/CJN.00470112","article-title":"Obstetric Nephrology: Renal Hemodynamic and Metabolic Physiology in Normal Pregnancy","volume":"7","author":"Odutayo","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_52","unstructured":"(2025, October 14). Williams Obstetrics-NLM Catalog-NCBI, Available online: https:\/\/www.ncbi.nlm.nih.gov\/nlmcatalog\/101626979."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/dmd.107.018705","article-title":"Product Inhibition of UDP-Glucuronosyltransferase (UGT) Enzymes by UDP Obfuscates the Inhibitory Effects of UGT Substrates","volume":"36","author":"Fujiwara","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40262-016-0367-6","article-title":"Development of a Physiologically Based Pharmacokinetic\/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor\/Transporter Occupancy of Central Nervous System Drugs","volume":"55","author":"Alqahtani","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_55","unstructured":"(2025, December 12). PBPK Modeling to Support Bioavailability and Bioequivalence Assessment in Pediatric Populations-PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/40140126\/."}],"container-title":["International Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-8937\/5\/4\/58\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:31:43Z","timestamp":1766053903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-8937\/5\/4\/58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijtm5040058"],"URL":"https:\/\/doi.org\/10.3390\/ijtm5040058","relation":{},"ISSN":["2673-8937"],"issn-type":[{"value":"2673-8937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}